Venetoclax/Rituximab Combo Approved for CLL/SLL

FDA warns, however, about the possibility of TLS due to rapid tumor cell destruction.

Source: CancerNetwork - June 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news